Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Añadir filtros








Intervalo de año
2.
Arq. bras. cardiol ; 62(4): 251-254, abr. 1994. graf
Artículo en Portugués | LILACS | ID: lil-156270

RESUMEN

PURPOSE--To assess the effects of benazepril (ACE inhibitor) on arterial blood pressure (ABP) and left ventricular mass index (LVMI). METHODS--Nineteen patients (7 men, 12 women) with mean age 38.2 +/- 10.2 years, with mild to moderate hypertension were evaluated. Besides raised blood pressure, the necessary inclusion criterion was the presence of left ventricular hypertrophy detected by echocardiogram. After a wash-out period, all patients were given placebo followed by the active drug benazepril at a dose of 10 mg once a day. For those patients who did not achieve a satisfactory control of the blood pressure (BP) 25 mg of chlorthalidone was added. All patients underwent 180 days of benazepril treatment. RESULTS--The ABP was gradually controlled as follow: at seated position the systolic BP changed from 156.05 +/- 5.07 mmHg to 129 +/- 3.74 mmHg (p < 0.001) and the diastolic BP from 99.74 +/- 1.59 mmHg to 81.8 +/- 2.27 mmHg (p < 0.001). At orthostatic position the systolic BP changed from 156.9 +/- 5.35 mmHg to 124.28 +/- 5.33 mmHg (p < 0.001) and the diastolic BP from 101.7 +/- 1.34 to 81.36 +/- 2.81 (p < 0.001). The heart rate did not change significantly during the study. The LVMI decreased significantly from 182.4 +/- 9.2g/m2 to 122.6 +/- 4.2g/m2 (p < 0.001). CONCLUSION--Our data revealed that 100 per cent of the patients achieved satisfactory degrees of LVMI regression and in 34 per cent there was a normalization of it


Asunto(s)
Humanos , Masculino , Femenino , Benzazepinas/uso terapéutico , Hipertrofia Ventricular Izquierda/tratamiento farmacológico , Antihipertensivos/uso terapéutico , Hipertensión/tratamiento farmacológico , Benzazepinas/administración & dosificación , Administración Oral , Presión Arterial
3.
Braz. j. med. biol. res ; 24(10): 1071-9, 1991. ilus
Artículo en Inglés | LILACS | ID: lil-102092

RESUMEN

1. The present study was designed to examine the role of central epinephrine pathways in the control of stress-induced prolactin secretion in male adulto Wistar rats. 2. Intracerebroventricular adminsitration of two epinephrine synthesis inhibitors, SKF64139 (5 and 10 µg/rat) and LY 134046 (10 and 20 µg/rat), 6 h before the onset of immobilization stress blocked prolactin secretion in a dose-dependent manner. Prolactin values before stress were about 4.0 ng/ml and increased to almost 50 ng/ml in the control group. SKF 64139 injection in the higher dose (10 µg/rat) induced a complete blockade of the stress-induced prolactin release, whereas partial blockade was observed after the higher dose (20 µg/rat) of LY 134046. 3.Salbutamol pretreatment (10 µg/rat) completely restored stress-induced prolactin secretion in animals receiving a central injection of both epinephrine synthesis inhibitors under the same conditions as described above. 4. It is suggested that epinephrine pathways in the brain play an important role in the control of prolactin release occuring during immobilization stress


Asunto(s)
Animales , Masculino , Ratas , Benzazepinas/farmacología , Isoquinolinas/farmacología , Inhibidores de la Monoaminooxidasa/farmacología , Prolactina/metabolismo , Albuterol/farmacología , Benzazepinas/administración & dosificación , Inyecciones Intraventriculares , Isoquinolinas/administración & dosificación , Inhibidores de la Monoaminooxidasa/administración & dosificación , Prolactina/sangre , Ratas Endogámicas , Estrés Fisiológico/fisiopatología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA